Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

September 27, 2022

Study Completion Date

October 6, 2022

Conditions
Myocardial Infarction
Interventions
COMBINATION_PRODUCT

PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.

A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.

PROCEDURE

Surgery by sternotomy

The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.

Trial Locations (1)

08916

Hospital Universitari Germans Trias i Pujol, Badalona

All Listed Sponsors
collaborator

Germans Trias i Pujol Hospital

OTHER

lead

Fundació Institut Germans Trias i Pujol

OTHER

NCT03798353 - Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue | Biotech Hunter | Biotech Hunter